Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Boesenbergia rotunda extract, derived from the fingerroot plant (known as Krachai in Thailand), is a botanical medicine being investigated for its antiviral properties, particularly against SARS-CoV-2. Developed by researchers at Mahidol University, the extract contains bioactive prenylated flavonoids such as panduratin A and pinostrobin. In vitro studies have demonstrated that these compounds possess potent inhibitory activity against SARS-CoV-2 replication, potentially by targeting the viral 3C-like protease (3CLpro). Clinical trials are evaluating the extract as a treatment for asymptomatic or mild COVID-19 patients to prevent disease progression and hospitalization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on boesenbergia rotunda extract.